Craft

Regenxbio

Stock Price

$9.1

2024-10-29

Market Capitalization

$447.8 M

2024-10-29

Revenue

$170.4 M

FY, 2025

Regenxbio Summary

Company Summary

Overview
Regenxbio is a clinical-stage biotechnology company providing gene therapy product candidates for the treatment of retinal, metabolic, and neurodegenerative diseases. It offers a NAV Technology Platform, which uses viral vectors to deliver genes to cells.
Type
Public
Status
Active
Founded
2009
HQ
Rockville, MD, US | view all locations
Website
https://www.regenxbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Ken Mills

    Ken Mills, President and Chief Executive Officer, Director

  • Vit Vasista

    Vit Vasista, Chief Financial Officer

  • Olivier Danos

    Olivier Danos, Chief Scientific Officer

  • Patrick J. Christmas II

    Patrick J. Christmas II, Chief Legal Officer

Operating MetricsView all

New Pivotal Study Projects

2
100.0%

FY, 2022

Research Phase Products

1

FY, 2022

Phase I/II Trials Products

5

FY, 2022

LocationsView all

1 location detected

  • Rockville, MD HQ

    United States

    9804 Medical Center Dr

Regenxbio Financials

Summary Financials

Revenue (Q1, 2026)
$6.4M
Net income (Q1, 2026)
($90.1M)
Cash (Q1, 2026)
$15.2M
EBIT (Q1, 2026)
($83.4M)
Enterprise value
$503.6M

Footer menu